Spotlight
Clinical
Conferences
CME/CE
M.D. Anderson and AstraZeneca form neuropathic pain alliance
Oncology NEWS InternationalOncology NEWS International Vol 17 No 2
Volume 17
Issue 2
M.D. Anderson Cancer Center and AstraZeneca will collaborate to help advance the understanding of neuropathic pain caused by cancer chemotherapy.
HOUSTONM.D. Anderson Cancer Center and AstraZeneca will collaborate to help advance the understanding of neuropathic pain caused by cancer chemotherapy. The alliance will focus on identifying neurobiological differences between cancer patients who develop such pain and those who do not, and better understanding the mechanisms through which chemotherapies cause peripheral nerve dysfunctions.
Articles in this issue
NLST article not balanced, critic of screening trial asserts
M.D. Anderson and AstraZeneca form neuropathic pain alliance
Good nilotinib responses in imatinib-resistant AP-CML
Virus linked to Merkel cell carcinoma
Benefit of adjuvant RT/CT for pancreatic ca affirmed
Recurrence Score helps select node+ pts for chemo
For resectable liver mets: Preop chemotherapy or not?
Plerixafor boosts stem cell mobilization in myeloma pts
MRI shows second-hand smoke damage
Assay has high sensitivity for hard-to-detect SLN mets
Dasatinib effective in imatinib resistant/intolerant CML
ONI remembers Judah Folkman, founder of angiogenesis
New machine approved for adaptive RT
ONI sits down with Dr. Vincent DeVita
Making faster, better, more cost-effective clinical trials
Related Videos
Related Content
